Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
Earnings Data
Report Date
Apr 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.41Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Q4 2025
Earnings Call Date:Feb 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented multiple meaningful achievements: record SUBLOCADE and company revenues, strong adjusted EBITDA growth and margin expansion, clear commercial momentum (prescriber and new patient growth), disciplined cost targets, improved cash flow guidance, and a $400 million opportunistic buyback. Offsets include expected U.S. SUBOXONE pressure, rest-of-world optimization impacts, restructuring charges, gross-to-net volatility, reliance on SUBLOCADE for growth, and some R&D and debt-related uncertainties. On balance, the progress, upgraded profitability guidance, and capital deployment flexibility outweigh the risks and challenges discussed.Company Guidance
Record Company Revenue and Year-over-Year Growth
Total net revenue for 2025 was $1.24 billion, up 4% versus 2024; fourth quarter net revenue was $358 million, up 20% year-over-year.
SUBLOCADE Strong Performance
SUBLOCADE net revenue reached a record $856 million in 2025, a 13% increase versus 2024; Q4 SUBLOCADE net revenue was $252 million, up 30% year-over-year. Full-year SUBLOCADE dispense volume grew 7% in 2025, with Q4 dispense growth of 12% year-over-year and 6% sequentially. Company expects mid-teens SUBLOCADE dispense unit growth in 2026 and SUBLOCADE net revenue guidance of $905–945 million (≈ +8% at midpoint).
Commercial Momentum — Prescribers, New Patients, and DTC Impact
New patient starts in Q4 were up 25% year-over-year; total active SUBLOCADE prescribers and prescribers treating 5+ patients each grew ~14% year-over-year and ~6% sequentially. The 'Move Forward in Recovery' DTC campaign drove a 60% increase in branded online search volume in Q4 versus pre-launch, a 70% increase in usage of the Find a SUBLOCADE Treatment Provider tool, and CRM enrollments rose to ~1,400/month in Q4 from ~60/month prior to the campaign.
Adjusted EBITDA and Margin Improvement
Adjusted EBITDA was a record $428 million for 2025, up 20% year-over-year with a 500 basis point margin improvement. Q4 adjusted EBITDA rose 91% year-over-year to $142 million. 2026 guidance targets adjusted EBITDA of $535–575 million (≈ +30% at midpoint) and a target adjusted EBITDA margin of ~48%.
Cost Discipline and Operating Expense Targets
Non-GAAP operating expenses were $622 million for 2025 (down 5% year-over-year) and $164 million in Q4 (down 8% year-over-year). Company expects non-GAAP operating expenses of $430–450 million in 2026 and stated operating expenses will not exceed $450 million in 2026.
Strengthened Financial Profile and Capital Deployment
Paid the outstanding $295 million DOJ obligation in 2025, eliminating a legacy liability. Ended 2025 with gross cash and investments of $222 million and net leverage below 1x. Company expects ~ $300 million in cash flow from operations in 2026 and announced a new $400 million share repurchase authorization (up to 18 months) while prioritizing debt management and opportunistic M&A.
Pipeline Readiness and Clear BD Criteria
Two phase II trials completed at end of 2025 with database lock expected by end of Q1 2026 and top-line results in Q2. Company defined business development criteria: commercial-stage assets, peak sales potential >$200M, long runway (mid-to-late 2030s), and differentiated products.
INDV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INDV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $34.08 | $33.76 | -0.94% |
Oct 30, 2025 | $25.24 | $29.13 | +15.41% |
Jul 31, 2025 | $17.40 | $20.20 | +16.09% |
Apr 24, 2025 | $9.45 | $10.76 | +13.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Indivior PLC (INDV) report earnings?
Indivior PLC (INDV) is schdueled to report earning on Apr 23, 2026, Before Open (Confirmed).
What is Indivior PLC (INDV) earnings time?
Indivior PLC (INDV) earnings time is at Apr 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INDV EPS forecast?
Currently, no data Available